MMV-supported projects

Research

Lead optimization
- Pyrazines
  - GSK
- Phenotypic Lead
  - Mitsui Tanabe
- Intra-muscular
  - Bayer
- Phenotypic Lead
  - MGI
- GWT1
  - Eli Lilly
- Molecular Target
  - Dong Institute
- Azabenimidazole
  - UNCAMP

Candidate profiling
- Minipertoire
  - Novartis
- MMV1581373
  - Novartis
- MMV1793609
  - Novartis
- 4-aminoquinoline
  - Boston Children's Hospital
- Molecular Target
  - UCSF
- DHODH
  - Broad
- UT SW/ UW/ Monash
- Merck KGaA-UCT

Translational

Preclinical
- MMV1581373
  - Novartis
- MMV1591371
  - Janssen
- MMV183
  - (TropIQ)
- MMV646
  - (Jacobus)
- INK963
  - Novartis
- Atoguanil
  - (Qing)
- MMV533
  - (Sanofi)

Candidate
- P218
  - Janssen
- M5717
  - Merck KGaA
- MMV533
  - (Sanofi)

Human volunteers
- MMV200
  - Novartis
- Cipargam
  - Novartis
- Artesunate
  - Novartis

Product development

Preclinical
- Ferroquine
  - (Aurobindo)
- Artesunate
  - (Novartis)

Patient exploratory
- Cipargam
  - Novartis
- MMV200
  - (Novartis)

Patient confirmatory
- Dihydroartemisinin-piperazine
  - (Arihale)
- Tafenoquine
  - Novartis

Regulatory review
- Artemether-
  - lumefantrine
  - (Novartis)
- Sulfadoxine-
  - pyrimethamine-
  - amodiaquine
  - (Daiichi Sankyo)

Access

Approved/ERP
- Artemether-
  - lumefantrine
  - (Novartis)
- Sulfadoxine-
  - pyrimethamine-
  - amodiaquine
  - (Fonavexa Pharma)
- Artemesunate for Injection
  - (Fonavexa Pharma)
- Artemesunate
  - (Novartis)
- Artemesunate-
  - rectal capsules
  - (Sanoxya Pharma)
- Artemesunate-
  - rectal capsules
  - (Sanoxya Pharma)
- Artemesunate-
  - rectal capsules
  - (Sanoxya Pharma)
- Artemesunate-
  - rectal capsules
  - (Sanoxya Pharma)

Footnotes:
- Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of AMQ and ASAQ.
- Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
- Pediatric formulation.
- via a bioequivalence study. Past partners are in brackets (-).

Brand names: 1: Coartem® Dispersible; 2: Artesun®; 3: Larinate® 60mg; 4: Euartesin®; 5: Pyramax® tablets or granules; 6: ASAQ Winthrop®; 7: SPALQ-COTM; 8: Suprya®; 9: 100mg Artesunate Rectocaps; 10: Artescap®; 11: Kzenis/Krintafel (Trademarks owned or licensed by GSK)
Footnotes: MMV-supported projects

Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.


<table>
<thead>
<tr>
<th>Target Product Profiles</th>
<th>indicated by bars at the bottom of each compound box</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-day cure, artemisinin-based combination therapies (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Severe malaria treatment / pre-referral intervention (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Intermittent preventive treatment (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Products targeting prevention of relapse for <em>P. vivax</em> (TPP-1)</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis (TPP-2)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target Candidate Profiles</th>
<th>activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asexual blood stages</td>
<td>Burrows et al., 2013 (TCP-1,2) Burrows et al., 2017 (TCP-1)</td>
</tr>
<tr>
<td>Relapse prevention</td>
<td>(TCP-3a) TCP-3</td>
</tr>
<tr>
<td>Transmission reduction</td>
<td>(TCP-3b) TCP-5,6</td>
</tr>
<tr>
<td>Causal prophylaxis</td>
<td>(TCP-4) TCP-4</td>
</tr>
</tbody>
</table>

September 2020